|Bid||1,039.00 x 0|
|Ask||1,039.50 x 0|
|Day's Range||1,071.00 - 1,092.00|
|52 Week Range||994.80 - 1,489.00|
|PE Ratio (TTM)||58.20|
|Earnings Date||Feb 21, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||1,420.53|
LONDON/MILAN (Reuters) - Mergers and acquisitions dominated European share trading on Tuesday, while strength in oil stocks after a pipeline shutdown helped lift a key regional benchmark index to five-week highs. The pan-European STOXX 600 index climbed 0.7 percent to its highest level since Nov. 9, while euro zone blue chip stocks rose 0.4 percent, helped by a late drop in the euro. Gemalto surged 34.6 percent after French tech consultancy Atos tabled an all-cash bid valuing the Dutch cybersecurity company at 4.3 billion euros.
Genmab was Europe's second biggest biotech company, until its partner Johnson & Johnson bought Switzerland's Actelion for $30 billion (£22.30 billion) this year and propelled the Danish antibody specialist to the top spot. Now some investors wonder if the same fate might await Genmab, worth $12 billion, given the soaraway success of its blood cancer drug Darzalex. J&J sells the drug and pays Genmab a royalty of 12 to 20 percent.
By Helen Reid LONDON (Reuters) - European shares enjoyed a recovery on Thursday, snapping their longest losing streak since October 2016 as the cyclical sectors which had driven a market-wide sell-off ...
Genmab A/S and Seattle Genetics, Inc. announced today a decision to start a Phase II study of tisotumab vedotin in patients with recurrent and/or metastatic cervical cancer.
Genmab A/S and Seattle Genetics, Inc. announced today that Seattle Genetics, Inc. has exercised its option to co-develop tisotumab vedotin. The companies originally entered into a commercial license and collaboration agreement in October 2011 under which Seattle Genetics had the right to exercise a co-development option for tisotumab vedotin at the end of Phase I clinical development.
Gains by cyclical sectors helped push European stocks higher on Thursday while heavy losses in Dixons Carphone after a profit warning dominated trading. Dixons Carphone shares plummeted as much as 29 percent after the mobile phone retailer downgraded expectations for full-year profit, reflecting tougher conditions in the mobile market as customers hold on to handsets for longer. "With the December results some way off and Black Friday week (of retail discounts) looming, Dixons will be under pressure to provide additional detail on today's complex variables in coming weeks," said Stifel analysts.
Danish biotech drugmaker Genmab expects sales of Darzalex, used to fight cancer in bone marrow, to surpass $1 billion this year to become a blockbuster drug, the company said on Wednesday. The $1 billion a year required to achieve blockbuster is now in sight, with net sales of Darzalex -- approved in November 2015 and is marketed by Johnson & Johnson (J&J) -- expected to reach between $1.1 billion and $1.3 billion this year, up from $572 million in 2016, Genmab said. Genmab receives tiered royalties from J&J on its sales and expects to receive Darzalex royalties of between 930 million Danish crowns and 1,100 million crowns ($132 million-$156 million) and 800 million crowns in milestone payments this year.
Danish biotech drugmaker Genmab's Darzalex, which is used to fight cancer in bone marrow and marketed by Johnson & Johnson, has the potential to achieve annual peak annual sales as high as $13 billion, its chief executive told Reuters. "It could work in other blood cancers as well as in solid tumours. Genmab expects sales of Darzalex to surpass $1 billion this year, the company said on Wednesday.